Ascelia Pharma

Ascelia Pharma Long-term Debt

The Long-Term Debt of Ascelia Pharma (ACE.ST) as of Nov 22, 2026 is 72,000.00 SEK.

Long-term Debt

72,000.00SEK

Last updated:

Long-Term Debt of Ascelia Pharma is 2025 72,000.00 SEK. Long-Term Debt of Ascelia Pharma was 2024 0.00 SEK. It decreases by % higher compared to the previous year.

The Ascelia Pharma Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
146,000.00 SEK
Jan 1, 2019
96,000.00 SEK
Jan 1, 2020
956,000.00 SEK
Jan 1, 2021
553,000.00 SEK
Jan 1, 2022
193,000.00 SEK
Jan 1, 2023
176,000.00 SEK
Jan 1, 2024
0.00 SEK
Jan 1, 2025
72,000.00 SEK
The Ascelia Pharma Long-term Debt history
YEARLong-term DebtYoY
72,000.00SEK—
0.00SEK-100.00%
176,000.00SEK-8.81%
193,000.00SEK-65.10%
553,000.00SEK-42.15%
956,000.00SEK+895.83%
96,000.00SEK-34.25%
146,000.00SEK—
0.00SEK—
0.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ascelia Pharma Stock analysis

What does Ascelia Pharma do? Ascelia Pharma AB develops pharmaceutical products for cancer treatment, focusing on underappreciated drug candidates. The company's pipeline includes Mangoral, a medical imaging drug for liver MRI in patients with impaired kidneys, which has completed phase II clinical trials, and Oncoral, a tablet formulation of irinotecan for gastric cancer treatment, currently in phase I development. Ascelia generates revenue through the development and potential commercialization of these drug candidates, targeting oncology markets with unmet medical needs. The firm identifies and acquires derisked investigational drug candidates, aiming to make them available to cancer patients. Mangoral addresses liver metastases detection in impaired kidney patients, while Oncoral targets gastric cancer treatment. Ascelia's business model relies on advancing these candidates through clinical trials to secure partnerships or regulatory approvals for market entry. Ascelia Pharma AB is headquartered in Malmö, Skåne, and employs 24 full-time staff. The company went public via IPO on March 13, 2019. Its revenue model centers on progressing its pipeline to attract potential partners or buyers for its drug candidates, with no mention of current sales or external funding sources beyond the IPO. Ascelia Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ascelia Pharma stock

Long-Term Debt of Ascelia Pharma is 72,000.00 SEK in 2025.

On Eulerpool you can find the complete historical development of Long-Term Debt Ascelia Pharma since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Ascelia Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Ascelia Pharma

All Key Metrics — Ascelia Pharma